The global Alzheimer ’s disease (AD) diagnostics and therapeutics market is currently composed of five major marketed drugs, donepezil, galantamine, rivastigmine, memantine, and combination of donepezil/memantine; a multitude of brain imaging diagnostics tests; and a highly invasive technique of CSF analysis for AD biomarker identification. The end product/service offered in this market today is the same as what was offered about a decade ago. During the last decade, there were many drugs that made it to the late stages of clinical trials, but almost all of them were rejected for market approval, due to toxicity and safety issues. Today, many drugs are again in the late pipeline stages of drug development for AD. In fact, there are more candidates than ever and there are many novel drug applicants, aimed at addressing the actual pathological cause of AD, which the currently marketed drugs are unable to address. Additionally, the current modality in advanced and late AD diagnosis is composed of brain imaging studies, which sometimes need to be conducted over a wide timespan of months to arrive at the correct diagnosis. The second line of diagnosis is composed of CSF tests, which requires an invasive procedure of lumbar puncture.

1. INTRODUCTION

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

5. MARKET SEGMENTATION

6. COMPANY PROFILES AND COMPETITIVE LANDSCAPE

7. MARKET OPPORTUNITIES AND FUTURE TRENDS